These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 17087808

  • 41. Giving patients with erectile dysfunction the opportunity to try all three available phosphodiesterase type 5 inhibitors contributes to better long-term treatment compliance.
    Ljunggren C, Hedelin H, Salomonsson K, Ströberg P.
    J Sex Med; 2008 Feb; 5(2):469-75. PubMed ID: 18086159
    [Abstract] [Full Text] [Related]

  • 42. Comparison of efficacy and satisfaction profile, between penile prosthesis implantation and oral PDE5 inhibitor tadalafil therapy, in men with nerve-sparing radical prostatectomy erectile dysfunction.
    Megas G, Papadopoulos G, Stathouros G, Moschonas D, Gkialas I, Ntoumas K.
    BJU Int; 2013 Jul; 112(2):E169-76. PubMed ID: 23253640
    [Abstract] [Full Text] [Related]

  • 43. Does educational status affect a patient's behavior toward erectile dysfunction?
    Salonia A, Abdollah F, Gallina A, Pellucchi F, Castillejos Molina RA, Maccagnano C, Rocchini L, Zanni G, Rigatti P, Montorsi F.
    J Sex Med; 2008 Aug; 5(8):1941-8. PubMed ID: 18399948
    [Abstract] [Full Text] [Related]

  • 44. Improvement in sexual quality of life of the female partner following vardenafil treatment of men with erectile dysfunction: a randomized, double-blind, placebo-controlled study.
    Martín-Morales A, Graziottin A, Jaoudé GB, Debruyne F, Buvat J, Beneke M, Neuser D.
    J Sex Med; 2011 Oct; 8(10):2831-40. PubMed ID: 21679304
    [Abstract] [Full Text] [Related]

  • 45. Validation of stopwatch measurements of erection duration against responses to the sexual encounter profile and international index of erectile Function in patients treated with a phosphodiesterase type 5 inhibitor.
    Shaw JW, Reardon G, Sandor DW, Rosen RC, Ferguson DM.
    J Sex Med; 2010 Mar; 7(3):1147-59. PubMed ID: 20113397
    [Abstract] [Full Text] [Related]

  • 46. Dropout in the treatment of erectile dysfunction with PDE5: a study on predictors and a qualitative analysis of reasons for discontinuation.
    Carvalheira AA, Pereira NM, Maroco J, Forjaz V.
    J Sex Med; 2012 Sep; 9(9):2361-9. PubMed ID: 22616766
    [Abstract] [Full Text] [Related]

  • 47. Successful withdrawal of oral long-acting nitrates to facilitate phosphodiesterase type 5 inhibitor use in stable coronary disease patients with erectile dysfunction.
    Jackson G, Martin E, McGing E, Cooper A.
    J Sex Med; 2005 Jul; 2(4):513-6. PubMed ID: 16422846
    [Abstract] [Full Text] [Related]

  • 48. Integrating partners into erectile dysfunction treatment: improving the sexual experience for the couple.
    Dean J, Rubio-Aurioles E, McCabe M, Eardley I, Speakman M, Buvat J, de Tejada IS, Fisher W.
    Int J Clin Pract; 2008 Jan; 62(1):127-33. PubMed ID: 18028387
    [Abstract] [Full Text] [Related]

  • 49. Improving the sexual quality of life of couples affected by erectile dysfunction: a double-blind, randomized, placebo-controlled trial of vardenafil.
    Fisher WA, Rosen RC, Mollen M, Brock G, Karlin G, Pommerville P, Goldstein I, Bangerter K, Bandel TJ, Derogatis LR, Sand M.
    J Sex Med; 2005 Sep; 2(5):699-708. PubMed ID: 16422828
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. The treatment of erectile dysfunction study: focus on treatment satisfaction of patients and partners.
    Brock G, Chan J, Carrier S, Chan M, Salgado L, Klein AH, Lang C, Horner R, Gutkin S, Dickson R.
    BJU Int; 2007 Feb; 99(2):376-82. PubMed ID: 17155989
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. Couple satisfaction to different therapeutic modalities for organic erectile dysfunction.
    Hassan A, El-Hadidy M, El-Deeck BS, Mostafa T.
    J Sex Med; 2008 Oct; 5(10):2381-91. PubMed ID: 18179457
    [Abstract] [Full Text] [Related]

  • 57. Low-intensity extracorporeal shock wave therapy--a novel effective treatment for erectile dysfunction in severe ED patients who respond poorly to PDE5 inhibitor therapy.
    Gruenwald I, Appel B, Vardi Y.
    J Sex Med; 2012 Jan; 9(1):259-64. PubMed ID: 22008059
    [Abstract] [Full Text] [Related]

  • 58. Factors that predict changing the type of phosphodiesterase type 5 inhibitor medication among men in the UK.
    Kell PD, Hvidsten K, Morant SV, Harnett JP, Bridge S.
    BJU Int; 2007 Apr; 99(4):860-3. PubMed ID: 17378846
    [Abstract] [Full Text] [Related]

  • 59. An analysis of treatment preferences and sexual quality of life outcomes in female partners of Chinese men with erectile dysfunction.
    Li HJ, Bai WJ, Dai YT, Xu WP, Wang CN, Li HZ.
    Asian J Androl; 2016 Apr; 18(5):773-9. PubMed ID: 26459780
    [Abstract] [Full Text] [Related]

  • 60. A 6-month, prospective, observational study of PDE5 inhibitor treatment persistence and adherence in Middle Eastern and North African men with erectile dysfunction.
    El-Meliegy A, Rabah D, Al-Mitwalli K, Mostafa T, Hussein T, Istarabadi M, Lei Y, Gurbuz S.
    Curr Med Res Opin; 2013 Jun; 29(6):707-17. PubMed ID: 23540436
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.